Phase III OUTMATCH trial showed omalizumab improved treatment completion, reduced adverse events, and outperformed multiallergen oral immunotherapy in multifood allergy.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
A Phase III randomized clinical trial has shown that omalizumab (Xolair) outperformed omalizumab-facilitated multiallergen oral immunotherapy (MOIT) in patients with multiple food allergies, primarily because substantially fewer patients discontinued treatment due to adverse events. The findings, published online in JAMA Pediatrics, come from Stage 2 of the OUTMATCH trial and provide the first head-to-head comparison of anti-IgE monotherapy and multiallergen oral immunotherapy in this patient population.
Scientific and Clinical Context
Food allergy affects an estimated 8% to 10% of children and adults, with 30% to 86% of affected individuals allergic to multiple foods. These patients face a higher risk of accidental exposure, anaphylaxis, and reduced quality of life despite strict dietary avoidance.
Omalizumab is a monoclonal antibody that binds circulating immunoglobulin E (IgE), suppressing allergic immune responses and lowering the risk of severe reactions after accidental food exposure. The drug received US FDA approval in 2024 to reduce allergic reactions associated with one or more food allergies. Oral immunotherapy gradually increases allergen exposure to induce desensitization but requires prolonged dose escalation and carries a higher risk of treatment-related allergic reactions.
Trial Details
The multicenter, double-blind, placebo-controlled OUTMATCH Stage 2 trial (NCT03881696) enrolled 117 participants aged 1 to 55 years with confirmed allergy to peanuts and at least two additional foods, including milk, egg, wheat, cashew, hazelnut, or walnut.
All participants first received 16 weeks of open-label omalizumab before randomization to receive either omalizumab plus placebo oral immunotherapy or omalizumab-facilitated MOIT. The oral immunotherapy regimen targeted a maintenance dose of 1,000 mg of protein per food, or up to 3,000 mg across three foods, an intensive protocol that investigators later suggested contributed to the higher treatment burden.
The primary endpoint was successful tolerance of a cumulative 4,044 mg or greater of protein across all three study foods without dose-limiting symptoms after 52 weeks.
In the intention-to-treat analysis, 36% of patients receiving omalizumab achieved the primary endpoint compared with 19% receiving MOIT (odds ratio, 2.6; 95% CI, 1.1-6.3; P=0.03). However, the per-protocol analysis showed no significant difference between groups, indicating similar efficacy among participants who completed treatment.
The difference was largely explained by markedly higher treatment completion with omalizumab. Eighty-eight percent (51/58) of participants receiving omalizumab completed the study compared with 51% (30/59) receiving MOIT, with most MOIT withdrawals linked to treatment-related adverse events.
Omalizumab also demonstrated superior performance across several secondary endpoints. At the clinically relevant 444 mg cumulative protein threshold, which reflects protection against typical accidental food exposures, 72% of omalizumab-treated participants tolerated all three allergens compared with 39% in the MOIT group. The biologic also improved tolerance across multiple higher cumulative dose thresholds and several individual food allergens.
Safety Findings
Safety strongly favored omalizumab throughout the study.
Patients receiving MOIT experienced significantly higher rates of treatment-related complications, including serious adverse events (31% vs 0%), adverse events leading to treatment discontinuation (22% vs 0%), and epinephrine-treated reactions (37% vs 7%) compared with the omalizumab group. Three participants receiving active MOIT also developed biopsy-confirmed eosinophilic esophagitis.
Executive Perspective
Investigators concluded that the higher treatment success observed with omalizumab was driven largely by its superior tolerability rather than greater efficacy among participants who completed therapy. They suggested that the ambitious maintenance target, simultaneous treatment of three food allergens, rapid dose escalation, and protocol-related dosing constraints likely contributed to the higher adverse event and discontinuation rates in the MOIT group.
Future Development
The OUTMATCH findings strengthen evidence supporting omalizumab monotherapy as a treatment option for patients with multiple food allergies who require protection from accidental allergen exposure while avoiding the greater treatment burden associated with oral immunotherapy.
The investigators emphasized that additional studies comparing anti-IgE therapy, oral immunotherapy, and combination strategies, including long-term outcomes and cost-effectiveness analyses, will help define the most appropriate treatment approach for individual patients.
Reference
Treatment of Multifood Allergy with Omalizumab or Multiallergen Oral Immunotherapy
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.